Back to discover
Drug

Eicosapentaenoic Acid

In clinical development
Emerging researchLate-stage developmentSteady momentum
Also known as EPA, EPA - Eicosapentaenoic acid, ICOSAPENT, Icosapentaenoic acid+21 more

EPA, EPA - Eicosapentaenoic acid, ICOSAPENT, Icosapentaenoic acid, Icosapento, Icosapentum, Mi-Omega, Natelle, Ocean Blue Nutritionals Omega-3 1450, Sea-Omega, Timnodonic acid, Eicosapentaenoic Acid (EPA), (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate, (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid, (all-Z)-5,8,11,14,17-eicosapentaenoic acid, 5,8,11,14,17-Icosapentaenoic acid, 5,8,11,14,17-eicosapentaenoic acid, all-cis-5,8,11,14,17-eicosapentaenoic acid, all-cis-5,8,11,14,17-icosapentaenoic acid, all-cis-icosa-5,8,11,14,17-pentaenoic acid, cis-5,8,11,14,17-EPA, cis-5,8,11,14,17-eicosapentaenoic acid, cis-delta(5,8,11,14,17)-Eicosapentaenoic acid.

RxNorm90ChEMBLCHEMBL460026UNIIAAN7QOV9EA
4
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Differential Thrombogenesis Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Mediated by High-Density Lipoprotein (HDL)

Clinical trial2025-10-01Results expected Q3 2027 · ClinicalTrials.gov

Immunomodulatory Effects of Omega-3 Fatty Acids: Mechanistic Insights and Health Implications.

Research2025-03-30Molecular nutrition & food research

Omega-3 fatty acids for cardiovascular event lowering.

Research2024-06-01European journal of preventive cardiology

Phase 3 Long-term Study to Evaluate the Safety and Efficacy of MND-2119 in Patients With Hypertriglyceridemia

Clinical trial2021-07-14Completed · ClinicalTrials.gov

Effect of Omega-3 Fatty Acid, Eicosapentaenoic Acid, and Its Metabolites in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase

Clinical trial2021-05-21Terminated · ClinicalTrials.gov

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.

Research2020-12-01JAMA

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.

Research2020-03-26Arteriosclerosis, thrombosis, and vascular biology

MND-2119 Phase 3 Study to Evaluate the Efficacy and Safety of MND-2119 Compared to EPADEL CAPSULES 300 in Patients With Hypertriglyceridemia

Clinical trial2019-06-29Completed · ClinicalTrials.gov

CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation

Clinical trial2017-04-10Results posted · ClinicalTrials.gov

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

Clinical trial2017-03-23Results posted · ClinicalTrials.gov

Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters

Clinical trial2014-07-18Results posted · ClinicalTrials.gov

The Effect of Two Dose Levels of Eicosapentaenoic Acid (EPA) on Apoptosis and Cell Proliferation in the Colonic Mucosa of Patients With a History of Colonic Polyps.

Clinical trial2008-06-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Eicosapentaenoic Acid
Aliases & brands
EPAEPA - Eicosapentaenoic acidICOSAPENTIcosapentaenoic acidIcosapentoIcosapentumMi-OmegaNatelleOcean Blue Nutritionals Omega-3 1450Sea-OmegaTimnodonic acidEicosapentaenoic Acid (EPA)(5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid(all-Z)-5,8,11,14,17-eicosapentaenoic acid5,8,11,14,17-Icosapentaenoic acid5,8,11,14,17-eicosapentaenoic acidall-cis-5,8,11,14,17-eicosapentaenoic acidall-cis-5,8,11,14,17-icosapentaenoic acidall-cis-icosa-5,8,11,14,17-pentaenoic acidcis-5,8,11,14,17-EPAcis-5,8,11,14,17-eicosapentaenoic acidcis-delta(5,8,11,14,17)-Eicosapentaenoic acid
RxNorm CUI
90
ChEMBL ID
CHEMBL460026
UNII
AAN7QOV9EA

Clinical trials

11 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
11
registered trials across all phases
LATEST COMPLETION 2021
1
Active studies
1
Recruiting
7
Late-stage (III+)
9
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 11
Early Phase 11Phase 11Phase 1 / 21Phase 21Phase 2 / 31Phase 34Phase 41Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia

CompletedPH IVUniversity of Stellenboschn=842005

Phase 3 Long-term Study to Evaluate the Safety and Efficacy of MND-2119 in Patients With Hypertriglyceridemia

CompletedPH IIIMochida Pharmaceutical Company, Ltd.n=1202021

MND-2119 Phase 3 Study to Evaluate the Efficacy and Safety of MND-2119 Compared to EPADEL CAPSULES 300 in Patients With Hypertriglyceridemia

CompletedPH IIIMochida Pharmaceutical Company, Ltd.n=5802019

Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters

CompletedPH IIIMassachusetts General Hospitaln=1962013

The Effect of Two Dose Levels of Eicosapentaenoic Acid (EPA) on Apoptosis and Cell Proliferation in the Colonic Mucosa of Patients With a History of Colonic Polyps.

CompletedPH II/IIIS.L.A. Pharma AGn=1202008

Recent completions

Trials that read out recently, adding to the completed evidence base.

Phase 3 Long-term Study to Evaluate the Safety and Efficacy of MND-2119 in Patients With Hypertriglyceridemia

CompletedPH IIIMochida Pharmaceutical Company, Ltd.n=1202021

MND-2119 Phase 3 Study to Evaluate the Efficacy and Safety of MND-2119 Compared to EPADEL CAPSULES 300 in Patients With Hypertriglyceridemia

CompletedPH IIIMochida Pharmaceutical Company, Ltd.n=5802019

CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation

CompletedPH IIUniversity of Pittsburghn=572015

Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters

CompletedPH IIIMassachusetts General Hospitaln=1962013

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

CompletedN/AH. Lee Moffitt Cancer Center and Research Instituten=362010

The Effect of Two Dose Levels of Eicosapentaenoic Acid (EPA) on Apoptosis and Cell Proliferation in the Colonic Mucosa of Patients With a History of Colonic Polyps.

CompletedPH II/IIIS.L.A. Pharma AGn=1202008

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20202025
Major research themes4
Fatty Acids, Omega-32Cardiovascular Diseases1Dietary Supplements1Immunologic Factors1
Journals, researchers & institutions
Top journals
  • Arteriosclerosis, thrombosis, and vascular biology1
  • European journal of preventive cardiology1
  • JAMA1
  • Molecular nutrition & food research1
Leading researchers
  • Bhatt DL2
  • Mason RP2
  • Ağagündüz D1
  • Agrawal R1
  • Ballantyne CM1
  • Barter PJ1
  • Bash D1
  • Bodur M1
Leading institutions
free-text, unnormalised
  • Brigham and Women's Hospital2
  • Academic Medical Center1
  • Ankara University1
  • Baylor College of Medicine1
  • Center for Cardiovascular Disease Prevention1
  • Cleveland Clinic Coordinating Center for Clinical Research1

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Triglycerides

Studied across 3 of the same disease areas as Eicosapentaenoic Acid in the shared literature.

3 shared diseases1 shared paper
Corn Oil

Studied across 2 of the same disease areas as Eicosapentaenoic Acid in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials